AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Fool
Apogee Therapeutics Inc (APGE) shares surged 48.3% in pre-market trading, reaching a 52-week high, following news of AbbVie agreeing to acquire the company for approximately $10.9 billion.
The acquisition deal, valued at $135.11 per share, is expected to integrate Apogee's clinical-stage treatments into AbbVie's portfolio, enhancing its position in the immunology sector. This strategic move is anticipated to drive growth, particularly in respiratory diseases, and reflects strong investor optimism regarding the future potential of the combined entities.
The market's positive reaction underscores the significance of this acquisition, as it not only boosts Apogee's stock price but also highlights the ongoing consolidation in the biopharmaceutical sector, which could lead to further advancements in treatment options for patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APGE
Wall Street analysts forecast APGE stock price to fall
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 132.880
Low
83.00
Averages
105.67
High
137.00
Current: 132.880
Low
83.00
Averages
105.67
High
137.00
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE) for its sale to AbbVie at $135.11 per share, potentially infringing on shareholder rights.
- Shareholder Rights: Open Lending Corporation (NASDAQ: LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, with Halper Sadeh LLC urging shareholders to be aware of their rights and options.
- Legal Consultation: Huntsman Corporation (NYSE: HUN) is selling to Olin Corporation for 0.5476 shares of Olin per Huntsman share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their legal rights.
- Compensation Requests: Avanos Medical, Inc. (NYSE: AVNS) is being sold to American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may seek increased compensation and other relief measures to protect shareholder interests.
See More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion at $135.11 per share in cash, representing a 49% premium, aimed at enhancing its drug portfolio and expanding its market share in immunology.
- Pipeline Advantages: Apogee brings a promising pipeline of experimental drugs targeting dermatologic, respiratory, and other immunological diseases, particularly its lead candidate, zumilokibart, which could become a best-in-class treatment for atopic dermatitis with a more convenient dosing schedule.
- Strategic Significance: AbbVie's CEO highlighted that this acquisition will further enrich its immunology portfolio, addressing significant patient needs in areas like atopic dermatitis and asthma, thereby reinforcing the company's leadership in inflammatory disease treatment.
- Financial Outlook: Although the deal is expected to close in the third quarter, AbbVie does not anticipate any impact on adjusted earnings per share until 2032, indicating a long-term strategic approach to diversifying its revenue base.
See More
AbbVie Acquires Apogee for $10.9 Billion to Strengthen Immunology Business
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash, which represents a 49% premium over the stock's closing price prior to the announcement, aimed at diversifying its immunology business and enhancing profitability.
- Pipeline Potential: Apogee brings a promising pipeline of experimental drugs targeting dermatologic and respiratory diseases, with its lead candidate, zumilokibart, potentially being a best-in-class treatment for atopic dermatitis that offers a more convenient dosing schedule, addressing significant patient needs.
- Strategic Importance: AbbVie's CEO highlighted that this acquisition will expand its immunology portfolio in critical areas of patient need, helping to reduce reliance on blockbuster drugs Skyrizi and Rinvoq, which generated $6.6 billion in net revenue in the first quarter alone.
- Financial Outlook: While the acquisition is expected to close in the third quarter, AbbVie does not anticipate any contribution to its adjusted earnings per share until 2032, indicating a long-term strategic approach to enhancing its market position.
See More
Intel Shares Hit All-Time High as Market Confidence Grows
- Intel Stock Surge: Intel shares climbed to an all-time high of $141.45, driven by growing confidence in its chip manufacturing business and positive outlook on partnerships with major tech firms like Apple, which is expected to enhance future earnings.
- Keel Infrastructure Transformation: Keel Infrastructure reached a four-year high of $7.37 as investors welcomed its strategic shift from cryptocurrency mining to AI infrastructure, with the company raising $458 million to support its data center projects.
- Apogee Therapeutics Acquisition Boost: Apogee Therapeutics stock surged to $133 after AbbVie agreed to acquire the company for $135.11 per share in a $10.9 billion all-cash deal, indicating large pharmaceutical firms' ongoing interest in promising drug development.
- Strong Market Performance: Intel, Keel Infrastructure, and Apogee Therapeutics all achieved new 52-week highs, reflecting investor confidence in long-term growth in infrastructure, advanced computing, and healthcare sectors, with Intel and Keel both gaining over 5% and Apogee soaring 46%.
See More
Apogee Therapeutics Acquired by AbbVie at 49% Premium
- Merger Agreement: Apogee Therapeutics Inc. has officially signed a $10.9 billion acquisition agreement with pharmaceutical giant AbbVie Inc., with AbbVie set to acquire Apogee at $135.11 per share, representing a 49.5% premium over its closing price of $90.38 last Friday, indicating strong market confidence in the deal.
- Stock Surge: Following the acquisition announcement, Apogee's stock soared to a high of $133 before closing at $132.55, marking a 46.66% increase from the previous trading day, reflecting investor optimism about its future prospects.
- Strategic Importance: AbbVie's acquisition aims to strengthen its portfolio in immunology, as Apogee's diverse pipeline focuses on elevating care standards for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases, further solidifying AbbVie's market position.
- Regulatory Approval Timeline: The transaction is subject to regulatory and shareholder approvals, with expectations for completion in the third quarter of this year, establishing a timeline for integration and future growth for both companies.
See More
AbbVie Acquires Apogee for Approximately $10.9 Billion
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion, which underscores AbbVie's robust presence and expansion strategy in the pharmaceutical market.
- Shareholder Value Enhancement: The agreed purchase price represents a nearly 47% premium over Apogee's previous closing price, which is expected to garner support from Apogee shareholders, further solidifying AbbVie's market position in the biopharmaceutical sector.
- Drug Development Potential: Apogee's leading drug, zumilokibart, has shown promising results in clinical trials for eczema and asthma, with its long-lasting effects providing a competitive edge in the market, likely contributing to significant future revenues for AbbVie.
- Financial Impact Analysis: Although the acquisition is projected to negatively impact AbbVie's non-GAAP EPS in the short term, analysts anticipate that the earnings per share will remain strong at $14.24 and $16.25 over the next two years, reflecting market confidence in AbbVie's stock.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Apogee Therapeutics, Inc. (NASDAQ: APGE) for its sale to AbbVie at $135.11 per share, potentially infringing on shareholder rights.
- Shareholder Rights: Open Lending Corporation (NASDAQ: LPRO) is being sold to ANV Group Holdings Ltd. for $3.15 per share, with Halper Sadeh LLC urging shareholders to be aware of their rights and options.
- Legal Consultation: Huntsman Corporation (NYSE: HUN) is selling to Olin Corporation for 0.5476 shares of Olin per Huntsman share, and Halper Sadeh LLC offers no-cost legal consultations to help shareholders understand their legal rights.
- Compensation Requests: Avanos Medical, Inc. (NYSE: AVNS) is being sold to American Industrial Partners for $25.00 per share, and Halper Sadeh LLC may seek increased compensation and other relief measures to protect shareholder interests.
See More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion at $135.11 per share in cash, representing a 49% premium, aimed at enhancing its drug portfolio and expanding its market share in immunology.
- Pipeline Advantages: Apogee brings a promising pipeline of experimental drugs targeting dermatologic, respiratory, and other immunological diseases, particularly its lead candidate, zumilokibart, which could become a best-in-class treatment for atopic dermatitis with a more convenient dosing schedule.
- Strategic Significance: AbbVie's CEO highlighted that this acquisition will further enrich its immunology portfolio, addressing significant patient needs in areas like atopic dermatitis and asthma, thereby reinforcing the company's leadership in inflammatory disease treatment.
- Financial Outlook: Although the deal is expected to close in the third quarter, AbbVie does not anticipate any impact on adjusted earnings per share until 2032, indicating a long-term strategic approach to diversifying its revenue base.
See More
AbbVie Acquires Apogee for $10.9 Billion to Strengthen Immunology Business
- Acquisition Overview: AbbVie is acquiring Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash, which represents a 49% premium over the stock's closing price prior to the announcement, aimed at diversifying its immunology business and enhancing profitability.
- Pipeline Potential: Apogee brings a promising pipeline of experimental drugs targeting dermatologic and respiratory diseases, with its lead candidate, zumilokibart, potentially being a best-in-class treatment for atopic dermatitis that offers a more convenient dosing schedule, addressing significant patient needs.
- Strategic Importance: AbbVie's CEO highlighted that this acquisition will expand its immunology portfolio in critical areas of patient need, helping to reduce reliance on blockbuster drugs Skyrizi and Rinvoq, which generated $6.6 billion in net revenue in the first quarter alone.
- Financial Outlook: While the acquisition is expected to close in the third quarter, AbbVie does not anticipate any contribution to its adjusted earnings per share until 2032, indicating a long-term strategic approach to enhancing its market position.
See More
Intel Shares Hit All-Time High as Market Confidence Grows
- Intel Stock Surge: Intel shares climbed to an all-time high of $141.45, driven by growing confidence in its chip manufacturing business and positive outlook on partnerships with major tech firms like Apple, which is expected to enhance future earnings.
- Keel Infrastructure Transformation: Keel Infrastructure reached a four-year high of $7.37 as investors welcomed its strategic shift from cryptocurrency mining to AI infrastructure, with the company raising $458 million to support its data center projects.
- Apogee Therapeutics Acquisition Boost: Apogee Therapeutics stock surged to $133 after AbbVie agreed to acquire the company for $135.11 per share in a $10.9 billion all-cash deal, indicating large pharmaceutical firms' ongoing interest in promising drug development.
- Strong Market Performance: Intel, Keel Infrastructure, and Apogee Therapeutics all achieved new 52-week highs, reflecting investor confidence in long-term growth in infrastructure, advanced computing, and healthcare sectors, with Intel and Keel both gaining over 5% and Apogee soaring 46%.
See More
Apogee Therapeutics Acquired by AbbVie at 49% Premium
- Merger Agreement: Apogee Therapeutics Inc. has officially signed a $10.9 billion acquisition agreement with pharmaceutical giant AbbVie Inc., with AbbVie set to acquire Apogee at $135.11 per share, representing a 49.5% premium over its closing price of $90.38 last Friday, indicating strong market confidence in the deal.
- Stock Surge: Following the acquisition announcement, Apogee's stock soared to a high of $133 before closing at $132.55, marking a 46.66% increase from the previous trading day, reflecting investor optimism about its future prospects.
- Strategic Importance: AbbVie's acquisition aims to strengthen its portfolio in immunology, as Apogee's diverse pipeline focuses on elevating care standards for patients with dermatologic, respiratory, and other related inflammatory and immunological diseases, further solidifying AbbVie's market position.
- Regulatory Approval Timeline: The transaction is subject to regulatory and shareholder approvals, with expectations for completion in the third quarter of this year, establishing a timeline for integration and future growth for both companies.
See More
AbbVie Acquires Apogee for Approximately $10.9 Billion
- Acquisition Overview: AbbVie has signed a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, totaling approximately $10.9 billion, which underscores AbbVie's robust presence and expansion strategy in the pharmaceutical market.
- Shareholder Value Enhancement: The agreed purchase price represents a nearly 47% premium over Apogee's previous closing price, which is expected to garner support from Apogee shareholders, further solidifying AbbVie's market position in the biopharmaceutical sector.
- Drug Development Potential: Apogee's leading drug, zumilokibart, has shown promising results in clinical trials for eczema and asthma, with its long-lasting effects providing a competitive edge in the market, likely contributing to significant future revenues for AbbVie.
- Financial Impact Analysis: Although the acquisition is projected to negatively impact AbbVie's non-GAAP EPS in the short term, analysts anticipate that the earnings per share will remain strong at $14.24 and $16.25 over the next two years, reflecting market confidence in AbbVie's stock.
See More
